Taken collectively, our results indicate that treatment with (TC3-S)2 is able to reverse the IL-10-induced MΦ iron-release phenotype with functional consequences on cellular iron content, tumor cell proliferation and metastatic behavior. Here, IL10 is linked to neoplasm.